Related Experiment Video
Updated: Jun 22, 2026

Isolation of Endothelial Progenitor Cells from Human Umbilical Cord Blood
Published on: September 14, 2017
Endothelial progenitor cells as a therapeutic option in peripheral arterial disease
A J Devanesan1, K A Laughlan, H R S Girn
1Leeds Vascular Institute, Leeds General Infirmary, Leeds, West Yorkshire, UK.
Background:
Endothelial progenitor cells (EPC) are a subpopulation of bone-marrow mononuclear cells that are capable of generating new blood vessels in areas of ischaemia or infarction. This review examines the regenerative potential of EPC to ameliorate peripheral ischaemia.
Methods:
An online search was done using OVID Medline Search, PubMed, and Cochrane Review Database, for all reviews and original articles in English concerning progenitor or bone-marrow mononuclear cells.
Results And Conclusion:
There are many controversies in EPC research, especially in the areas of identification, characterization, and therapeutic use. Both animal and human studies have shown benefits from using EPC to combat peripheral arterial and cerebrovascular disease. To bring EPC into wider clinical use, larger controlled clinical trials and better methods of augmenting EPC function and lifespan are required. Until then EPC should be used under robust trial conditions with ethical approval.
More Related Videos
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease I: Introduction
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Regulation of Angiogenesis and Blood Supply
iPS Cell Differentiation

